Overview: Vesselon’s Transformative Co-formulation Method
Emerging Dynamics in the Biopharmaceutical Industry: Mergers & Acquisitions Trends
How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Vesselon Virtual Town Hall: A Glimpse into the Future of Intravenous Drug Development
Introducing the First On-site Co-Formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs
Vesselon Protects and Expands Drug Franchises
Drug maker is seeking strategic relationship to deliver unprecedented levels of efficacy by making tissues more receptive to drugs.
Drug Discovery Trends
Merck and Vesselon Preclinical Study Reports Dramatic Tumor Pharmacokinetics Findings
Complete regression of both primary and distant tumors in 44% of enrolled subjects achieved with intravenous administration.
Vesselon Acquires FDA Approved Lipid Microsphere Imagent
“By changing the rate of progression or stopping cancer in its tracks, Vesselon can change the cancer landscape.”
Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation & Tumor Regression
Sonoporation, the temporal cell membrane openings that can arise after ultrasound exposure, has been explored across many preclinical applications but has lacked translational momentum.